Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jul;31(3):547-558.
doi: 10.1016/j.soc.2022.03.012.

Management of Synovial Sarcoma and Myxoid Liposarcoma

Nadia Hindi  1 , Rick L Haas  2
Affiliations
Review

Management of Synovial Sarcoma and Myxoid Liposarcoma

Nadia Hindi et al. Surg Oncol Clin N Am. 2022 Jul.

Abstract

Synovial sarcoma and myxoid liposarcoma are translocation-related sarcomas, with a high risk of developing distant metastasis, which often affect young patients and which are sensitive to chemo and radiotherapy. Surgery is the mainstay of therapy in localized disease. In these entities, perioperative radiotherapy is frequently administered, and chemotherapy is evaluated in patients with high-risk limb/trunk wall tumors in which an advantage in overall survival has been shown in the latest clinical trials. In the advanced setting, new strategies, such as cellular therapy are being developed in these histologic types, with promising, although still preliminary, results.

Keywords: Advanced soft tissue sarcoma; Cellular therapy; Chemotherapy; Myxoid liposarcoma; Radiotherapy; Synovial sarcoma; Targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Disclosure N. Hindi has received honoraria from PharmaMar (expert testimony and invited speaker) and performs work in clinical trials or contracted research for which her institution received financial support from PharmaMar, Eli Lilly and Company, Adaptimmune Therapeutics, AROG, Bayer, Eisai, Lixte, Karyopharm, Deciphera, GSK, Novartis, Blueprint, Nektar, Forma, Amgen, and Daiichi Sankyo. R.L. Haas has no conflicts of interest to declare.